BTG expects full-year revenues at 'top end' of guidance

Specialist healthcare company BTG said Thursday it expects full-year revenues at the 'top end' of it guidance following strong trading of the group's medical products.

Specialist healthcare company BTG said Thursday it expects full-year revenues at the 'top end' of it guidance following strong trading of the group's medical products.

The FTSE 250 business said the last three months have wielded positive results, particularly from acute care items.

The board anticipates revenues for the year to March 31st 2013 to reach the higher point of its estimate between £205m to £215m.

Financial results were boosted by operational progress including its interventional medicine business, according to BTG.

Last year BTG was granted approval in the US for its PARAGON Bead and PRECISION Bead products for the treatment of intrahepatic cholangiocarcinoma (cancer of the bile ducts) and uveal melanoma (eye cancer) respectively.

BTG is also seeking approval of Varisolve as a comprehensive treatment for varicose veins which will be submitted to the US Food & Drug Administration (FDA) within the next few days.

During the period, BTG made headway in partnered programmes. Zytiga received US and European label extensions to treat men with metastatic castration-resistant prostate cancer who have not received prior chemotherapy.

The FDA accepted a standard review of Sanofi and its subsidiary Genzyme's Biologics License Application for the approval of Lemtrada for the treatment of relapsing multiple sclerosis. A response to the application is expected in the second half of this year.

"We have continued to make excellent operational and financial progress and now expect full year revenues to be around the top end of previous guidance," said Chief Executive of BTG, Louise Makin.

"With the imminent submission of the Varisolve and the good progress in our beads business, we are on track with our strategic priorities and focused on executing our growth strategy."

Shares were up 4.02% to 333.40p at 08:49 Thursday.

RD

Recommended

How to profit from pampered pets beyond the pandemic
Share tips

How to profit from pampered pets beyond the pandemic

Covid-19 has greatly boosted ownership. But the market had been expanding for years, and demographic, cultural and medical trends all point to long-te…
30 Jul 2021
Share tips of the week – 30 July
Share tips

Share tips of the week – 30 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
30 Jul 2021
Robinhood is going public – should you invest?
US stockmarkets

Robinhood is going public – should you invest?

Online stockbroking app Robinhood is going public on the US stock exchange. Saloni Sardana looks at whether it's worth a punt.
29 Jul 2021
Three sustainable stocks that are doing well by doing good
Share tips

Three sustainable stocks that are doing well by doing good

Professional investor Peter Michaelis of the Liontrust Sustainable Investment Team picks three stocks to buy that are helping to create a cleaner, saf…
26 Jul 2021

Most Popular

Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Three companies that are reaping the rewards of investment
Share tips

Three companies that are reaping the rewards of investment

Professional investor Edward Wielechowski of the Odyssean Investment Trust highlights three stocks that have have invested well – and are able to deal…
19 Jul 2021